Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948130 | 0.87 | LMNA (0.55) | CYP2D6ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4572801 | 0.86 | SIGMAR1 (0.60) | HRH3MEN1KMT2A | |
| SCHEMBL7852144 | 0.85 | FAAH (0.51) | CYP2D6ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL12536930 | 0.85 | ALDH1A1 (0.52) | CYP2D6ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL16760957 | 0.84 | SIGMAR1 (0.56) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL19049378 | 0.84 | HRH3 (0.60) | HRH3CYP2D6ALDH1A1HTTMEN1 | |
| SCHEMBL12660179 | 0.84 | ALDH1A1 (0.72) | HRH3CYP2D6ALDH1A1HTTMEN1 | |
| SCHEMBL2652152 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HTTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL13649189 | 0.82 | KDM4E (0.66) | HRH3CYP2D6ALDH1A1HTTMEN1 | |
| SCHEMBL28144346 | 0.82 | SIGMAR1 (0.45) | ALDH1A1HTTLMNACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021108803-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2003011836-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220201-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | HRH3 3514/4885CYP2D6 4826/4885ALDH1A1 3104/4885 |
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | HRH3 3514/4885CYP2D6 4826/4885ALDH1A1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.